The accelerator, dubbed Mayflower BioVentures, will establish independent cell and gene therapy companies aimed at advancing the development of Mayo Clinic technologies through preclinical and early feasibility studies, according to an Aug. 31 press release.
The goal of Mayflower BioVenture is to advance new cures for serious and complex conditions through cell and gene therapies.
The accelerator’s team will consist of clinical leaders from Mayo Clinic and operational and investment experience from Hibiscus.
Any revenue collected from the accelerator will go toward Mayo Clinic’s patient care, education and research.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.